ALKEM2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member ALKEM2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ALKEM 2021-04-01 2022-03-31 2022-01-24 INR Millions Third quarter Single segment The Company is exclusively engaged in pharmaceutical business 2021-10-01 2021-12-31 Unaudited Standalone 21808400000.00 632400000.00 22440800000.00 7331900000.00 2694600000.00 -1748200000.00 3400800000.00 72600000.00 584300000.00 5406700000.00 17742700000.00 4698100000.00 0.00 4698100000.00 808300000.00 -481100000.00 327200000.00 0.00 4370900000.00 0.00 0.00 0.00 0.00 4370900000.00 -10500000.00 4360400000.00 0.00 0.00 239100000.00 2 36.56 36.56 0.00 0.00 36.56 36.56 1. The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 3 February 2022 and subsequently approved by the Board of Directors at its meeting held on 4 February 2022. The auditors have issued an unmodified report on the financial results for the quarter and nine months ended 31 December 2021. 2. Pursuant to the Board of Directors approval at its meeting held on 25 May 2021 on the proposed plan for restructuring of the USA business operations by bringing both the subsidiaries namely, S & B Pharma Inc, USA (“S & B”) and The PharmaNetwork LLC, USA (“TPNC”) under a single umbrella by removing intermediary holding company S & B Holdings BV, Netherlands (“S & B BV”), the Company on 4 October 2021 has consummated the transaction whereby TPNC acquired 100% shares of S&B from the Company in exchange of TPNC’s shares. Subsequently, with effect from 5 January 2022, S & B now stands dissolved and all its assets and liabilities are now transferred by TPNC as capital contribution in its subsidiary S & B Pharma LLC. 3. The Company has made an assessment of the recoverable value of investment in its subsidiaries taking into account the decline in operational performance, changes in the outlook of future profitability, weaker market conditions, among other potential indicators. Accordingly, during the year ended 31 March 2021, an impairment loss of Rs.127.8 Million was recognised towards investment in Alkem Laboratories Corporation, Philippines, a wholly owned subsidiary of the Company in accordance with IND AS 36 ‘Impairment of assets’ and the same has been disclosed as an 'Exceptional item'. 4. The Board of Directors at its meeting held on 4 February 2022 have declared an interim dividend of Rs. 30 (Rupees Thirty only) per equity share (1500% on the face value of Rs. 2 each) for the financial year ending 2021-22. 5. The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Single segment 2021-04-01 2021-12-31 Unaudited Standalone 68235000000.00 1456600000.00 69691600000.00 20837500000.00 8311500000.00 -2460300000.00 11038100000.00 248200000.00 1639700000.00 14401500000.00 54016200000.00 15675400000.00 0.00 15675400000.00 2714100000.00 -1682400000.00 1031700000.00 0.00 14643700000.00 0.00 0.00 0.00 0.00 14643700000.00 -31200000.00 14612500000.00 0.00 0.00 239100000.00 2 122.48 122.48 0.00 0.00 122.48 122.48 Other expenses 5406700000.00 Other expenses 14401500000.00